Business
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
- Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":"- Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs advancing; development candidate selections for lead programs expected Q4 2022 to H1 2023 - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2022 financial and operating results. “The past few months have been characterized by increasing validation and momentum for Voyager’s TRACER capsid platform,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Pfizer’s license of a novel capsid for a rare neurologic disease target reflects the potential of our platform to help overcome key limitations of current gene therapy approaches. Further, the data we presented at ESGCT characterizing a novel CNS receptor for one of our capsid families, along with data demonstrating high blood-brain barrier penetration of a capsid at doses as low as 2% of that used in current approved intravenous gene therapies, serve to increase our confidence that our preclinical capsid data has the potential to translate in human clinical trials and could be transformational for patients. Our pipeline programs for Alzheimer’s disease, Parkinson’s disease and ALS are progressing well, and we look forward to announcing development candidates for all three lead programs over the next several quarters, as previously guided.” Key Milestones Achieved in Q3 2022 and Subsequent Period: Pfizer license of novel TRACER capsid: Voyager announced in October that Pfizer, Inc. exercised in September its option to license a novel capsid generated from Voyager’s TRACERTM capsid discovery platform to help enable a potential gene therapy program against an undisclosed rare neurologic disease target. Voyager previously received a $30 million upfront option grant payment and, following the close of Q3 2022, received a $10 million option exercise payment. Voyager is also eligible to receive up to $290 million in development, regulatory, and commercial milestones, plus mid- to high-single-digit tiered royalties associated with the licensed capsid. Voyager re...